Skip to main content
. 2013 Sep 11;8(9):e73834. doi: 10.1371/journal.pone.0073834

Figure 5. Phenotypic results after baculovirus-mediated dsJHER472 administration.

Figure 5

A. Targeting the SnJHER 472 bp part after baculovirus administration of dsJHER472 in 5th instar d3 larvae Left. Infection with BmNPV-BmA::GFP/BmA::dsLuciferase virus 7th day post infection (N = 200), a. Dorsal and b. Lateral view of BmNPV-BmA::GFP/BmA::dsLuciferase infected animals. Right. Infection with BmNPV-BmA::GFP/ BmA::JHERloop virus 7th day post infection (N = 200), 1. Type I of developmental abnormalities of BmNPV-BmA::GFP/BmA::JHERloop infected animals, melanized epidermis in the posterior side. a. Dorsal and b. Abdominal view of BmNPV-BmA::GFP/BmA::JHERloop infected animals. 2. Type II of developmental abnormalities of BmNPV-BmA::GFP/BmA::JHERloop infected animals, melanized epidermis in the lateral side. a. Dorsal, b. Lateral and c. Abdominal view of BmNPV-BmA::GFP/BmA::JHERloop infected animals. 3. Type III of developmental abnormalities of BmNPV-BmA::GFP/BmA::JHERloop infected animals, melanized epidermis in the whole body, dorsal view. Types I, II, and III were presented in 14 % of the BmNPV-BmA::GFP/BmA::JHERloop infected animals (N = 200). B. Targeting the SnJHER 472 bp part after baculovirus administration of dsJHER472 in 6th instar d9 larvae. Developmental abnormalities of larval-pupal intermediates shared in both BmNPV-BmA::GFP/BmA::dsLuciferase and BmNPV-BmA::GFP/BmA::JHERloop infected animals (1→5). A. Normal pupa. The type 3., of larval-pupal intermediate that was presented only in BmNPV-BmA::GFP/BmA::JHERloop infected animals. Scale bar: 1 cm